Inhibrx Biosciences (INBX) Net Income (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Net Income of -$32.8 million for Q4 2025, up 31.4% year-over-year from -$25.0 million in Q4 2024, and up 6.87% quarter-over-quarter from -$35.3 million in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Net Income (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Net Income for 3 consecutive years, with -$32.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income rose 31.4% year-over-year to -$32.8 million; the TTM figure through Dec 2025 stood at -$140.1 million (down 108.3% YoY), while the FY2025 annual figure was -$140.1 million, down 108.3% from the prior year.
- Net Income advanced to -$32.8 million in Q4 2025 per INBX's latest filing, from -$35.3 million in the prior quarter.
- Across five years, Net Income topped out at $1.9 billion in Q2 2024 and bottomed at -$92.0 million in Q4 2023.
- Historically, Net Income has averaged $123.3 million across 3 years, with a median of -$43.9 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income soared 4048.85% — and 2025, when it plunged 101.54%.
- Inhibrx Biosciences' Net Income stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then jumped by 31.4% to -$32.8 million in 2025.
- Business Quant data shows INBX's Net Income at -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | -36.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.65 Mn |
| Dec 31, 2025 | -32.83 Mn |
| Sep 30, 2025 | -35.26 Mn |
| Jun 30, 2025 | -28.65 Mn |
| Mar 31, 2025 | -43.31 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -43.86 Mn |
| Jun 30, 2024 | 1.86 Bn |
| Mar 31, 2024 | -78.71 Mn |
| Dec 31, 2023 | -91.97 Mn |
| Sep 30, 2023 | -51.79 Mn |
| Jun 30, 2023 | -47.05 Mn |